Editorial
|
|
|
|
|
Risky approval of denosumab
|
|
|
|
Marketing Authorisations
|
|
|
|
|
Limited efficacy in fracture prevention, too many adverse effects
|
|
|
|
|
|
|
|
|
|
Data manipulation: not acceptable
|
|
|
|
|
|
|
|
|
|
No need to change standard practice
|
|
|
|
|
|
|
|
|
|
|
|
Even more harmful than the oral form
|
|
|
|
Adverse Effects
|
|
|
|
|
A British study of 600 cases
|
|
|
|
|
|
|
|
|
|
The risk should be discussed before prescribing
|
|
|
|
|
|
|
|
|
|
Definitely a do-not-use drug
|
|
|
|
|
|
|
|
|
|
|
|
Gemfibrozil a safer fibrate
|
|
|
|
|
|
|
|
|
|
Beware invasive dental procedures
|
|
|
|
|
|
|
|
|
|
Caution advised with all SSRIs
|
|
|
|
|
|
Reviews
|
|
|
|
|
Furosemide and trinitrine, despite the lack of a proven survival benefit
|
|
|
|
|
|
|
|
|
|
Management mostly based on the triggering malignancy
|
|
|
|
Outlook
|
|
|
|
|
Potentially dangerous packaging remains a significant problem
|
|
|
|
|
|
|
|
|
|
|
|
Failure of prepublication controls
|
|
|
|
|
|
|
|
|
|